Jianzan: EU approved cerdelga for the treatment of type 1 Gaucher's disease

Source: China Council for the promotion of drugs January 22, 2015, jianzan, a subsidiary of Sanofi, announced that the European Commission had approved cerdelga (eliglutat) capsule as the first-line treatment drug for adult patients with type 1 Gaucher disease A small number of adult patients whose cerdelga metabolism is too fast or whose metabolic rate is uncertain by genetic gene test in laboratory Cerdelga treatment will not be available Cerdelga was approved by the US Food and Drug Administration in August 2014, and its registration approval in other countries around the world is also in progress Cerdelga is expected to be listed in EU countries in 2015 and in the next few years Cerdelga is an effective and highly specific inhibitor of glucoside ceramide synthetase, which is widely distributed in tissues including bone Cerdelga can reduce the accumulation of glucuronide in cells and tissues of patients with type 1 Gaucher's disease Cerdelga has been approved in the European Union for the long-term treatment of adult patients with CYP2D6 metabolic deficiency (PMS), intermediate metabolism (IMS) or extensive metabolism (EMS) Original link: http:// ASPX? Type = FDP